Evidence map›Paper›PMID 39730966›Full record

ArticleAnnals of surgical oncology2025

Perioperative Changes in Serum Transaminases Levels Predicts Long-Term Survival Following Liver Resection of Hepatocellular Carcinoma.

Jingming Lu, Fumin Wang, Wei Zhang, Yaoxing Ren, Tian Yang, Francesca Ratti, Hugo P Marques, Silvia Silva, Olivier Soubrane, Vincent Lam and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Jingming Lu *Department of Hepatobiliary Surgery and Institute of Advanced Surgical Technology and Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
Fumin Wang *Department of Hepatobiliary Surgery and Institute of Advanced Surgical Technology and Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
Wei Zhang *
Yaoxing Ren *Department of Hepatobiliary Surgery and Institute of Advanced Surgical Technology and Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
Tian Yang *Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai, People's Republic of China.
Francesca RattiDepartment of Surgery, Ospedale San Raffaele, Milano, Italy.
Hugo P MarquesDepartment of Surgery, Curry Cabral Hospital, Lisbon, Portugal.
Silvia SilvaDepartment of Surgery, Curry Cabral Hospital, Lisbon, Portugal.
Olivier SoubraneDepartment of Hepatobiliopancreatic Surgery, APHP, Beaujon Hospital, Clichy, France.
Vincent LamDepartment of Surgery, Westmead Hospital, Sydney, Australia.
George A PoultsidesDepartment of Surgery, Stanford University, Stanford, CA, USA.
Irinel PopescuDepartment of Surgery, Fundeni Clinical Institute, Bucharest, Romania.
Razvan GrigorieDepartment of Surgery, Fundeni Clinical Institute, Bucharest, Romania.
Sorin AlexandrescuDepartment of Surgery, Fundeni Clinical Institute, Bucharest, Romania.
Guillaume MartelDepartment of Surgery, University of Ottawa, Ottawa, Canada.
Aklile WorknehDepartment of Surgery, University of Ottawa, Ottawa, Canada.
Alfredo GuglielmiDepartment of Surgery, University of Verona, Verona, Italy.
Tom HughDepartment of Surgery, School of Medicine, The University of Sydney, Sydney, Australia.
Luca AldrighettiDepartment of Surgery, Ospedale San Raffaele, Milano, Italy.
Itaru EndoYokohama City University School of Medicine, Yokohama, Japan.
Yi LyuDepartment of Hepatobiliary Surgery and Institute of Advanced Surgical Technology and Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
Xu-Feng ZhangDepartment of Hepatobiliary Surgery and Institute of Advanced Surgical Technology and Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China. xfzhang125@xjtu.edu.cn.
Timothy M PawlikDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. Tim.Pawlik@osumc.edu.ORCID http://orcid.org/0000-0002-7994-9870

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe sought to define whether and how hepatic ischemia/reperfusion (I/R) as manifested by perioperative aspartate aminotransferase (AST) and alanine aminotransaminase (ALT) levels impact long-term outcomes after curative-intent resection of hepatocellular carcinoma (HCC). PATIENTS AND

methodsIntrasplenic injection of HCC cells was used to establish a murine model of HCC recurrence with versus without I/R injury. Patients who underwent curative resection for HCC were identified from a multi-institutional derivative cohort (DC) and separate external validation (VC) cohort. Perioperative changes of transaminase levels were examined relative to the recurrence-free (RFS) and overall survival (OS) among patients following HCC resection.

resultsMice exposed to hepatic I/R injury were more likely to experience tumor recurrence, as well as higher luminescence signal intensity (all p < 0.05) versus mice with no I/R injury. Relative changes between AST and ALT (sum of AST/ALT ratios, SAAR) on postoperative day (POD) 1 and POD 3

conclusionsUse of routine labs such as AST and ALT can help identify patients at high risk of recurrence and mortality following HCC resection.

Indexed as

Alanine TransaminaseAspartate AminotransferasesBiomarkers, TumorCarcinoma, HepatocellularHepatectomyLiver NeoplasmsNeoplasm Recurrence, LocalReperfusion InjuryAgedAnimalsFemaleFollow-Up StudiesHumansMaleMiceMiddle AgedAlanine TransaminaseAspartate AminotransferasesBiomarkers, TumorHepatocellular carcinomaPrediction modelRecurrenceResectionTransaminase

Identifiers

PMID39730966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.